Global Hereditary Angioedema Therapeutic Market Segmentation, By Type (Type I Hereditary Angioedema (HAE), Type II Hereditary Angioedema (HAE), and Type III Hereditary Angioedema (HAE)), Drug Class (C-1 Esterase Inhibitors, Bradykynin B2 Receptor Antagonist, Kallikrein Inhibitors, Others), Application (Prophylaxis and Treatment), Route of Administration (Oral and Injectable), End User (Home Healthcare, Hospitals, Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031.
Hereditary Angioedema Therapeutic Market Analysis
The hereditary angioedema (HAE) therapeutic market is poised for substantial growth, driven by heightened awareness and significant advancements in treatment modalities. HAE, a rare genetic disorder characterized by recurrent and severe swelling, is seeing an uptick in therapeutic interventions due to improved diagnostic capabilities and a growing patient base. Recent innovations in diagnostics, such as enhanced genetic testing and biomarkers, have facilitated earlier and more accurate detection of the condition, leading to more personalized and effective treatments. Technological progress in therapeutic options, including the development of advanced C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors, has markedly improved treatment efficacy and patient outcomes.
Hereditary Angioedema Therapeutic Market Size
The global hereditary angioedema therapeutic market size was valued at USD 3.91 billion in 2023 and is projected to reach USD 7.63 billion by 2031, with a CAGR of 8.72% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hereditary Angioedema Therapeutic Market Trends
“Greater Emphasis on Personalized Care”
Greater emphasis on personalized care and advancements in treatment choices is contributing substantially in the hereditary angioedema (HAE) therapeutic market growth. Recent breakthroughs in therapeutics, such as subcutaneous C1-esterase inhibitors and oral bradykinin B2 receptor antagonists, demonstrate a shift toward more patient-centered solutions that are more convenient and effective than traditional intravenous treatments. The approval of novel medications such as Takeda's Takhzyro and BioCryst's Orladeyo illustrates such trend, which emphasizes tailored approaches, by improving both therapeutic efficacy and patient quality of life. Such developments reflect a broader trend of personalizing medicines to particular patient demands, which is driving significant market growth by making treatment alternatives more accessible and customizable.
Report Scope and Hereditary Angioedema Therapeutic Market Segmentation
|
Attributes
|
Hereditary Angioedema Therapeutic Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Takeda Pharmaceutical Company Limited (Japan), CSL (Australia), BioCryst Pharmaceuticals, Inc. (U.S.), Pharming (Netherlands), Ionis Pharmaceuticals (U.S.), Novartis AG (Switzerland), CENTOGENE N.V. (Germany), Sanofi (France), KalVista Pharmaceuticals (U.K.), Pfizer Inc. (U.S.), GSK plc. (U.K.), AstraZeneca (U.K.), Medtronic (U.S.), Lilly (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), AbbVie Inc. (U.S.), Incyte (U.S.), Bayer AG (Germany).
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Hereditary Angioedema Therapeutic Market Definition
Hereditary Angioedema (HAE) Therapeutics refer to the range of medical treatments specifically designed to manage and alleviate the symptoms of Hereditary Angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body. These therapeutics aim to prevent or reduce the frequency and severity of angioedema attacks, addressing the underlying pathophysiology of the condition. Treatments include medications such as C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors, which work to regulate and stabilize the body's inflammatory response. The goal of HAE therapeutics is to improve patient outcomes by minimizing swelling episodes, enhancing quality of life, and offering targeted and effective management options for this chronic condition.
Hereditary Angioedema Therapeutic Market Dynamics
Drivers
- Increasing Awareness Among Healthcare Professionals
Increasing awareness of hereditary angioedema (HAE) among healthcare professionals and patients has significantly improved the early and accurate diagnosis of the condition, driving up the demand for effective therapeutic options. For instance, recent initiatives by organizations such as the hereditary angioedema association (HAEA) have focused on educating both patients and clinicians about the signs and symptoms of HAE, resulting in better identification of the disorder. Consequently, the demand for targeted and innovative therapeutic options, such as c1-esterase inhibitors and bradykinin b2 receptor antagonists, has risen, driving market growth and improving patient outcomes.
- Rising Research and Development (R&D) Investments in Orphan Drug Development
Research and development (R&D) investments in orphan drug development is a pivotal driver of the hereditary angioedema (hae) therapeutic market. Orphan drugs, specifically designed to treat rare diseases such as HAE, benefit from significant financial and regulatory support due to their critical role in addressing unmet medical needs. For instance, the government of Canada announced a total investment of up to $1.5 billion in support of the first-ever national strategy for drugs for rare diseases to help increase access to, and affordability of, promising and effective drugs for rare diseases to improve the health of patients across Canada. Such substantial investment not only accelerates the discovery and commercialization of new treatments but also enhances patient outcomes and drives market expansion by addressing the specific needs of HAE patients.
Opportunities
- Development of Advanced Diagnostic Tools and Biomarkers
The development of advanced diagnostic tools and biomarkers for hereditary angioedema (HAE) is significantly enhancing early and accurate detection, leading to a higher number of diagnosed cases and a subsequent rise in demand for therapeutics. For instance, the introduction of next-generation sequencing (NGS) and genetic testing technologies has allowed for more precise identification of HAE subtypes and genetic mutations associated with the condition, thus facilitating earlier diagnosis. This advancement not only enables personalized treatment plans tailored to the specific genetic profile of patients but also supports more effective management of the disease. Consequently, the increased diagnostic accuracy and early intervention have driven greater demand for targeted therapies and innovative treatments, thus fueling market growth. Enhanced diagnostic capabilities also contribute to better disease monitoring and patient outcomes, further boosting the adoption of advanced therapeutics.
- Advancements in Combination Therapies
Advancements in combination therapies are presenting significant growth opportunities in the hereditary angioedema (HAE) therapeutic market by addressing multiple aspects of disease management simultaneously. Combining different therapeutic agents can provide synergistic effects, enhancing treatment efficacy and patient outcomes. For instance, the combination therapy of biocryst’s orladeyo, an oral kallikrein inhibitor, with takeda's takhzyro, which provides a multi-faceted approach to preventing HAE attacks and managing symptoms. Such integrated strategy not only improves therapeutic outcomes but also broadens the market appeal of combination therapies, as they cater to various patient needs and treatment regimens. As pharmaceutical companies explore and develop these combination therapies, they create new opportunities for market growth and improved patient care.
Restraints/Challenges
- Low Prevalence of the Disease
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, gastrointestinal tract, and airways. Due to its rarity, the prevalence of HAE is relatively low, affecting approximately 1 in 50,000 to 150,000 individuals globally. This limited patient population constrains the overall market size for hae therapeutics, making it a less attractive investment opportunity for pharmaceutical companies. Consequently, pharmaceutical companies may be deterred from investing heavily in research and development for HAE, impacting the availability and variety of treatment options.
- Complexity of Disease Management
Managing hereditary angioedema (HAE) presents a significant market challenge due to the multifaceted approach required for effective disease management. The condition necessitates both acute and prophylactic treatments, involving immediate interventions with intravenous c1-esterase inhibitors or bradykinin b2 receptor antagonists during attacks, and long-term prophylactic therapies such as daily or weekly c1-esterase inhibitors or oral kallikrein inhibitors to reduce attack frequency and severity. This complexity demands personalized treatment plans tailored to individual patient needs, attack frequency, and therapeutic response. The requirement for continuous monitoring and frequent adjustments to treatment regimens adds further difficulty, impacting patient adherence and healthcare provider efficiency. This intricate management landscape poses a challenge for pharmaceutical companies, as developing and delivering effective and adaptable therapies that address the diverse needs of hae patients requires substantial investment and innovation, potentially affecting market growth and accessibility.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Hereditary Angioedema Therapeutic Market Scope
The market is segmented on the basis of type, drug class, application, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Type I Hereditary Angioedema (HAE)
- Type II Hereditary Angioedema (HAE)
- Type III Hereditary Angioedema (HAE)
Drug Class
- C-1 Esterase Inhibitors
- Bradykinin B2 Receptor Antagonists
- Kallikrein Inhibitors
- Others
Application
- Prophylaxis
- Treatment
Route of Administration
- Oral
- Injectable
End User
- Home Healthcare
- Hospitals
- Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Hereditary Angioedema Therapeutic Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, type, drug class, application, route of administration, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the hereditary angioedema therapeutic market, driven by the continuous launch of innovative products by key pharmaceutical companies. The presence of well-established healthcare infrastructure and increased awareness of rare genetic disorders further supports market growth in the region. Additionally, favorable regulatory frameworks encourage faster approval of new therapies, boosting market expansion.
Asia-Pacific is projected to witness substantial growth in the hereditary angioedema therapeutic market, largely driven by rising patient awareness and improved diagnostic capabilities across the region. Increasing healthcare investments and the expansion of pharmaceutical companies into emerging markets further contribute to the growing availability of advanced treatments. Moreover, government initiatives aimed at enhancing healthcare infrastructure are supporting market expansion.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Hereditary Angioedema Therapeutic Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Hereditary Angioedema Therapeutic Market Leaders Operating in the Market Are:
- Takeda Pharmaceutical Company Limited (Japan)
- CSL (Australia)
- BioCryst Pharmaceuticals, Inc. (U.S.)
- Pharming (Netherlands)
- Ionis Pharmaceuticals (U.S.)
- Novartis AG (Switzerland)
- CENTOGENE N.V. (Germany)
- Sanofi (France)
- KalVista Pharmaceuticals (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc. (U.K.)
- AstraZeneca (U.K.)
- Medtronic (U.S.)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Amgen Inc. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Incyte (U.S.)
- Bayer AG (Germany)
Latest Developments in Hereditary Angioedema Therapeutic Market
- In December 2023, Ionis Pharmaceuticals has entered into a licensing agreement with Otsuka Pharmaceutical, granting Otsuka exclusive rights to market donidalorsen, a ligand-conjugated antisense therapy, for the treatment of hereditary angioedema (HAE) in Europe. Under the agreement, Ionis will manage the non-clinical and clinical development of the therapy, while Otsuka will handle its regulatory filings and oversee marketing efforts across Europe.
- In September 2024, KalVista Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat, an investigational oral plasma kallikrein inhibitor designed for the on-demand treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older.
SKU-